Market Overview

Propionic acidemia is a recessive genetic disorder in which the body is not able to make certain parts of lipids (fat) and protein properly. It is also known as an organic acid disorder, which causes an unusual buildup of particular organic acids in the body. These unusual levels of organic acids in the urine (organic aciduria), in the blood (organic acidemia), and in the tissues can be harmful and can lead to serious health problems. In majority of the cases, the signs of propionic acidemia become visible within a few days after birth. The starting symptoms include vomiting, loss of appetite, poor feeding, lack of energy (lethargy) and weak muscle tone (hypotonia), it can sometimes lead to more serious medical problems, including seizures, coma, heart abnormalities, and death. The market of propionic academia is expected to grow during the forecast period due to the rising research and development in the field of genetic disorders.

The outbreak of novel coronavirus has caused a disturbance in almost all the industries. The coronavirus pandemic has also affected the global propionic acidemia market. Due to the coronavirus, the flow of patients into the hospitals has been reduced which has led to the decline in the treatments. Production industries are being shuttered around the world due to the global restrictions causing an unusual technology and business model transformation. There has been a disruption in the supply of various APIs, especially import from due to the global restrictions, which is hampering the production of propionic academia drugs.

The rising incidence of various genetic disorders is the major factor driving the growth of the growth of the global propionic acidemia market. The increasing awareness regarding the propionic acidemia is also likely to boost the market. Furthermore, an increasing geriatric population, improvement in treatment and drug development, and changing lifestyle which leads to mutation in the genes across the globe are likely to boost the global propionic acidemia market. Apart from drivers, there are some restraints of propionic acidemia market such as high cost of treatment, and lack of awareness about the treatments especially in the underdeveloped countries as it is a very rare genetic disorder. In addition, the high out-of-pocket cost in emerging economies may restrict the growth of the global propionic acidemia market.

The global Propionic Acidemia market has been segmented on the basis of product type and distribution channel.

Based on the product type	Intravenous Glucose Fluid Therapy Antibiotics Intravenous Bicarbonate Biotin Supplement Biotin Supplement Medical Food
Based on the distribution channel	Hospital Pharmacies Retail Pharmacies Online Drug stores Drug Stores Hypercity Supermarkets E-Commerce

Based on the product type, the intravenous glucose fluid therapy segment is expected to hold a major share in the global propionic academia. Based on the distribution channel, hospitals are expected to be the most profitable segment in the global propionic acidemia market due to the advanced medical facilities and larger number of patients flow in the hospitals.

North America is expected to dominate the global propionic acidemia market due to the higher adoption of drugs and therapies in the region. North America is expected to be followed by Europe, due to the increasing number of hospitals and pharmaceutical industries in the region. Asia-Pacific is expected to have a significant growth in the global propionic acidemia market over the forecast period due to the increasing awareness about the propionic acidemia, rising healthcare expenditure and improvement in medical facilities. Latin America market is expected to experience the constant growth rate in the propionic acidemia market whereas the Middle East & Africa expected to be the least profitable market due to less advanced medical facilities.

The key participants operating in the global Propionic Acidemia market are: Cardiva Grifols SA, CSL Behring, Octapharma AG, Sanquin, Kedrion S.p.A, Shire, China Biologic Products Holdings, Inc, and others.